What is Novoeight®?

The first Novo Nordisk recombinant factor treatment was introduced in 1999.1 Continuing the focus on recombinant treatments, Novo Nordisk is proud to bring you Novoeight®—a treatment for hemophilia A. Learn how Novoeight® offers your patient:

  • Precise molecular design: Novoeight® is designed for reliability with molecular precision—contributing to its homogeneity and effective physiologic activity2-4
  • Efficacy he can count on: The efficacy of Novoeight® is supported by data from one of the largest clinical trials of a recombinant FVIII to date, which included 213 previously treated patients4
  • Portability: Novoeight® offers room temperature stability to support your patient's active lifestyle4
  • High standards for purity: Novoeight® undergoes an extensive 5-step purification process to offer purity2,4,5
     
Boy with hemophilia A


Julian, 13 years old,
lives with hemophilia A.

Find your Novo Nordisk Sales Representative

Talk with us

Connect with a local Novo Nordisk Representative to learn more about Novoeight®. He or she is an excellent source for information, and can direct you to many helpful tools and resources.


 

References: 1. Data on File. Novo Nordisk Inc; Plainsboro, NJ. 2. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349-359. 3. Kristensen AK, Kjalke M, Klausen NK, Ezban M, Vad K. Structural comparison of a new recombinant factor VIII molecule, turoctocog alfa, and commercially available FVIII products. Poster presented at: XXIV Congress of the International Society of Thrombosis and Haemostasis (ISTH); June 29-July 4, 2013; Amsterdam, The Netherlands. 4. Novoeight® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2014. 5. Data on file, Novo Nordisk Inc.; Plainsboro, NJ.


 


Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.